PSMAI cut-off value for mortality in men: 680.1 mm2/m2

EAU 2023: LuTectomy: A Prospective Study of Dosimetry, Safety and Potential Benefit of Upfront 177Lu-PSMA-617 Radioligand Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer

ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer

Dual-Time-Point Posttherapy 177Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome

EAU 2022: Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Detailed Outcome Data - Clinical Review Report: Letermovir (Prevymis) - NCBI Bookshelf

The TBI SBP Sweet Spot – Is 130-180 mmHg the New Normotension? – JournalFeed

ESMO 2022: Lu-PSMA for Prostate Cancer Treatment

Computed tomographic images at the the middle third lumbar vertebral

PDF) The association between psoas muscle area index and morbidity/mortality in laparoscopic gastric cancer surgery

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands

ESMO 2022: Lu-PSMA for Prostate Cancer Treatment

Reduced Acquisition Time per Bed Position for PET/MRI Using 68Ga-RM2 or 68Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177- PSMA-617 radioligand therapy, BMC Urology

PSMAI cut-off value for mortality in men: 680.1 mm2/m2

ASCO 2023: LuPARP: Phase 1 Trial of 177Lu-PSMA-617 and Olaparib in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)